Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 28,685	$ 14,042
Short-term investments		11,625
Accounts receivable, net of allowance for doubtful accounts of $76 and $0 as of December 31, 2021 and 2020, respectively	1,370	1,406
Inventories, net — current	4,433	3,812
Prepaid expenses and other current assets	900	811
Total current assets	35,388	31,696
Restricted cash		2,001
Property and equipment, net	2,291	3,539
Right of use assets	3,081	5,826
Inventories, net — noncurrent	2,494	3,485
Goodwill		408
Intangible assets, net	484	370
Other noncurrent assets	180	23
Total assets	43,918	47,348
Current liabilities:
Accounts payable and accrued expenses	3,638	4,105
Amounts due to related parties	64	80
Debt - current	0	1,141
Unearned revenue — current		8
Operating lease liability - current	1,074	717
Other current liabilities	264	263
Total current liabilities	5,040	6,314
Debt - noncurrent	0	2,105
Operating lease liability - noncurrent	2,220	5,389
Common stock warrant liabilities	3,392	2,708
Other noncurrent liabilities	2,070	2,280
Total liabilities	12,722	18,796
Commitments and contingencies (Note 17)
Stockholders’ equity:
Common stock, $0.001 par value 150,000,000 shares authorized as of December 31, 2021 and December 31, 2020; 22,184,235 and 13,450,861 shares issued and outstanding as of December 31, 2021 and December 31, 2020, respectively.	63	54
Additional paid-in capital	257,515	239,496
Accumulated deficit	(226,485)	(211,825)
Total Arcadia Biosciences stockholders’ equity	31,093	27,725
Non-controlling interest	103	827
Total stockholders' equity	31,196	28,552
Total liabilities and stockholders’ equity	$ 43,918	$ 47,348